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Laforin is a human protein associated with the glycogen metabolism, composed of two structurally and
functionally independent domains: a phosphatase catalytic domain and a substrate-binding module with
glycogen and starch afﬁnity. The main goal of this work is the development of a methodology for the
expression of the so far poorly characterized carbohydrate-binding module (CBM) of laforin, allowing
its study and development of biomedical applications. The laforin’s CBM sequence was originally cloned
by PCR from a humanmuscle cDNA library. The recombinant protein, containing laforin’s CBM fused to an
Arg-Gly-Asp sequence (RGD), was cloned and expressed using vector pET29a and recovered as inclusion
bodies (IBs). Refolding of the IBs allowed the puriﬁcation of soluble, dimeric and functional protein,
according to adsorption assays using starch and glycogen. Several other experimental approaches, using
both bacteria and yeast, were unsuccessfully tested, pointing towards the difﬁculties in producing the
heterologous protein. Indeed, this is the ﬁrst work reporting the production of the functional CBM from
human laforin.
 2010 Elsevier Inc. All rights reserved.Introduction
Laforin is a human dual speciﬁc phosphatase (DSP),2 coded by
the EPM2A gene, involved in the glycogen metabolism and impli-
cated with a human disorder – Lafora disease (LD), a progressive
myoclonus epilepsy [1–3].
Laforin presents the modular structure frequently found in the
CAZymes (enzymes that act on carbohydrates) [4], containing a
carbohydrate-binding module (CBM) at the N-terminus connected
by a linker to the C-terminal catalytic module [2]. Since each mod-
ule performs and folds independently, several CBM applications
have been described, namely its use as puriﬁcation and solubiliza-
tion tags in fusion proteins [5]. CBMs are classiﬁed according to the
sequence homology, the laforin’s CBM being assigned to family 20
(http://www.cazy.org/). The three-dimensional (3D) structure of
laforin (including its CBM domain) is still unknown. Furthermore,
recombinant laforin has been reported to aggregate easily, whichll rights reserved.
).
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etal ion afﬁnity chromatog-
ate-active enZymes database;explains the difﬁculty in obtaining enough protein for 3D structure
analyses [6].
It has been shown that this CBM binds complex carbohydrates
in vivo and in vitro [2], and the DSP motif can hydrolyze phospho-
tyrosine and phosphoserine/threonine substrates in vitro [1,6].
Laforin is the single human phosphatase containing a CBM and
has been shown to liberate phosphate from the complex carbohy-
drate amylopectin, whereas other phosphatases lack this activity
[7]. The main function of CBMs is to target the enzyme to the sub-
strate, increasing its activity, particularly in the case of insoluble
carbohydrates [5]. Besides binding laforin to glycogen, it was also
demonstrated that this CBM also drives the enzyme to Lafora
Bodies (LBs), dense aggregates of polyglucosan ﬁbrils structurally
similar to starch [8]. In addition, the CBM of laforin fused to the
DSP of vaccinia H1-related phosphatase still binds amylopectin
[7], thus the laforin-CBM remains functional when fused with
other peptides. In this context, bioactive peptides may be adsorbed
to biomaterials made of starch, through the fusion with CBM, in or-
der to achieve their functionalization for biomedical applications.
Among the bioactive molecules used to functionalize biomateri-
als, proteins of the extra-cellular matrix (ECM), poly-L-lysine (PLL)
and a natural adhesive protein extracted from mussel (MAP) [9]
have been successfully applied in promoting cell adhesion and pro-
liferation [10–13]. The Arg-Gly-Asp (RGD) motif – found in ECM
and blood proteins, such as ﬁbronectin, vitronectin, osteopontin,
collagens, thrombospondin, ﬁbrinogen, and von Willebrand factor
– was described as the major functional group responsible for
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als, through the immobilization of RGD on the material surface,
have been developed [15–17]. However, most of these strategies
involve the activation of either the polymer or the RGD-containing
sequence, to allow for the covalent binding. On the other hand, it
has been described that the RGD bioactivity can be conserved in fu-
sion proteins [18,19]; therefore, in this work, the RGD was fused to
the laforin’s CBM in order to produce a recombinant protein for
functionalization of starch material, by the adsorption of the pro-
tein through CBM afﬁnity. Indeed, several CBMs were already used
for protein targeting [20,21], including a CBM from family 20 with
starch afﬁnity, which was fused with RGD sequence to functional-
ize starch-based materials [22]. However, the utilization of a hu-
man protein seems a better choice when in vivo applications are
envisioned.
Although laforin has been cloned and puriﬁed, the application
of the laforin-CBM as a target partner has never been described.
Therefore, in this study, a strategy was developed to express, purify
and functionally characterize a recombinant protein containing the
human laforin-CBM fused to RGD tripeptide in Escherichia coli.
Material and methods
Reagents and strains
All reagents used were laboratory grade from Sigma–Aldrich
(St. Louis, USA), unless stated otherwise. E. coli strain XL1 Blue,
from Stratagene (Carlsbad, CA, USA) was used as bacterial host
for DNA cloning. For protein expression E. coli BL21 (DE3) strain
and the T7 plasmids pET29a and pET25b (+) were purchased from
Novagen (Madison, USA) and pGEX4-T1 from GE Healthcare. The
oligonucleotides presented in Table 1 were purchased from MWG
Biotech (Germany). Restriction enzymes and T4 DNA ligase were
purchased from Roche Diagnostics GmbH (Penzberg, Germany).
Pfu DNA polymerase used was from Stratagene, and the Maste-
rAmp 10X PCR Enhancer from EPICENTRE Biotechnologies. Throm-
bin protease and isopropyl b-D-1-thiogalactopyranoside (IPTG)
were from GE Healthcare. The theoretical molecular masses of
the recombinant proteins were calculated using the Compute pI/
Mw application from ExPASy Proteomics Server (http://www.exp
asy.ch/tools).
Gene cloning
The DNA coding sequence of the glycogen-binding module of
laforin was ampliﬁed using a human muscle cDNA library (CLON-
TECH). This sequence was used as template, to clone the CBM cod-
ing sequences by PCR with the RGD coding sequence being
introduced in the reverse primer. The PCR reactions were per-
formed using Pfu DNA polymerase (2.5 U), 0.5 mM of each primer
(forward and reverse according to Table 1), 1.2 mM MgSO4,
0.24 mM dNTP, 1.2X enzyme buffer, and 1.2X of PCR enhancer
solution. PCR conditions were: denaturation at 95 C, annealing
at 56 C and extension at 72 C, all steps for 45 s (this cycle was re-
peated 30 times).Table 1
Primers utilized to amplify the coding sequence in the different express
are in bold. The RGD coding sequence is underlined.
Plasmid Primer (50?30)
pET25b and pET29a For CATGCCATGGGGATGCGC
Rev GGAATTCATGGCTTGGTG
Rev CCGCTCGAGATCACCTCT
pGEX 4T1 For GGATCCATGCGCTTCCGC
Rev GGAATTCATGGCTTGGTG
Rev CCGCTCGAGATCACCTCTThe DNA coding sequences were cloned in different expression
system, allowing for the fusion of recombinant proteins with a
hexa-histidine tag (6xHis) on the C-terminal (pET expression
systems) or GST on the N terminal (pGEX expression system), for
puriﬁcation. The E. coli XL1 Blue was used as cloning strain and
expression was carried out in E. coli BL21 (DE3), E. coli BL21 star,
Origami or Tuner. Cell carrying the non-modiﬁed plasmid (without
DNA coding sequence) was used as negative control.
The integrity of cloned PCR products was veriﬁed by DNA
sequencing [23] using ABI PRISM310 Genetic Analyzer.
Recombinant His-tagged protein expression and puriﬁcation
The non-modiﬁed pET25, pET25-CBM or pET25-CBM-RGD was
used to transform E. coli expression host (BL21 DE3, Origami, Tu-
ner). Cells were cultivated in LB medium at 30 C until OD600
reached 0.4 and induced by adding IPTG to a ﬁnal concentration
of 0.1 mM for 16 h. At the end of fermentation, cells were har-
vested and periplasmic proteins recovered using the previously de-
scribed protocol [24].
To recover the cytoplasmatic proteins, cells were lysed in buffer
containing 50 mM Tris–HCl, pH 7.4, 300 mM NaCl, 0.1% b-mercap-
toethanol, 1 mM PMSF. After sonication, 0.6 M arginine and 1%
CHAPS (3-[(3-Cholamidopropyl) dimethylammonio]-1-propane-
sulfonate) were added to the lysate. The mixture was incubated
at 4 C, with gentle agitation for 16 h and centrifuged (30 min,
15 000 rpm, 4 C). The recombinant protein in the supernatant
was puriﬁed by immobilized metal ion afﬁnity chromatography
(IMAC), using 5 ml Nickel His-Trap columns (GE Healthcare)
according to the manufacturer’s instructions.
Expression and puriﬁcation of GST-tagged recombinant protein
Cells transformed with expression vectors pGEX-CBM, pGEX-
CBM-RGDor non-modiﬁed pGEXwere grown at 37 C in LBmedium
until OD600 reached 0.7. At this point temperature was lowered to
20 C and after 1 h protein expressionwas induced by IPTG addition
(0.1 mM ﬁnal concentration). twenty hours later, cells were har-
vested, resuspended in lysis buffer (10 mM Tris–HCl, 150 mMNaCl,
1 mM EDTA, pH 8.0) and incubated with deoxyribonuclease I
(100 lg/ml) and MgCl2 (100 mM). After DNA digestion, 100 ll of
Triton X-100 was added and the supernatant incubated with
Glutathione–Sepharose CL 4B (GE Healthcare). Protein elution was
performed using Tris buffer (50 mM Tris–HCl, pH 8.0) containing
10 mM reduced glutathione. Recombinant protein was treatedwith
thrombin protease (10 U/mg of recombinant protein), according to
the manufacturer’s instructions (GE Healthcare).
Recombinant protein expression in inclusion bodies (IBs), refolding,
and puriﬁcation
The culture of E. coli BL21 star (Invitrogen) transformed with
pET29a-CBM-RGD expression vector was grown in 1 L LB medium
with 30 lg/ml kanamycin at 37 C, 185 rpm in New Brunswick In-
nova 44R incubator shakers. The expression of CBM-RGD proteinion systems. The sequences recognized by the restriction enzymes
Restriction enzyme
TTCCGCTTTGGGG NcoI
GCCTGC EcoRI
CATGGTTGGTGGCCTGC XhoI
TTTGGGG BamHI
GCCTGC EcoRI
CATGGTTGGTGGCCTGC XhoI
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mid-log phase (OD600 0.6) to 0.5 mM ﬁnal concentration. After
3 h, 3.74 g of cells (wet weight) were harvested, resuspended in
50 ml of buffer A (50 mM Tris–HCl, 50 mM NaCl, pH 7.4), and lysed
by adding lysozyme (100 lg/ml). After freezing and thawing,
deoxyribonuclease I (100 lg/ml) and MgCl2 (100 mM) were added
and incubated at 4 C for 1 h. The IBs were then washed for 3 h
with 1 L of buffer A, centrifuged (at 10 000g for 20 min at 4 C),
and washed again for 3 h with 1 L of buffer A containing 0.1% Tri-
ton X-100 (v/v). Upon centrifugation (10 000 g for 20 min at 4 C),
puriﬁed IBs were dissolved in 50 ml of 8 M urea buffer (8 M urea,
0.1 M Tris, 1 mM glycine, 1 mM EDTA, pH 10.5) with 100 mM b-
mercaptoethanol and then the protein was refolded by rapid dilu-
tion (20-fold) at room temperature into 1 L of 20 mM Tris, 0.5 mM
oxidized/1.25 mM reduced glutathione, 0.5 mM DTT without prior
pH adjustment; the pH was then slowly (over a 2 h period) ad-
justed to 8.0 with 6 M HCl and the solution was kept at cold room
until puriﬁcation.
After 3–4 days to a week period the refolded CBM-RGD solution
was ﬁrst concentrated by tangential ﬂow ultraﬁltration (Pellicon 2;
Millipore) to approximately 150 ml, followed by a N2 pressurized
stirred cell concentrator (Amicon 8200 – Millipore) to 12–15 ml.
After ultracentrifugation to clarify the solution (100 000 g,
20 min, 4 C), the protein was applied to a 320–330 ml bed volume
HiLoad 26/60 Superdex 200 prep grade column (Amersham) pre-
equilibrated at room temperature with 20 mM Tris, 0.4 M urea,
pH 8.0 at 2.0 ml/min. Urea was kept in the puriﬁcation buffer in or-
der to prevent the protein aggregation [25].
The fractions eluted between 150 and 200 ml, corresponding to
non-aggregated forms of recombinant protein, were then com-
bined and further puriﬁed by ion exchange chromatography on a
1 ml Mono Q HR 5/5 column (GE Healthcare) using the same buffer
as for the Superdex 200 chromatographic experiment with a linear
gradient of NaCl (0–0.5–1 M) at 0.75 ml/min.Recombinant protein analysis
Recombinant protein was analyzed either by Coomassie stained
12% SDS–PAGE (sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis) and 10% native PAGE, which was used to evaluate pro-
tein aggregation. For MW determination the protein was analyzed
by gel ﬁltration chromatography on a 24 ml bed volume Superdex
200 10/300 GL column (GE Healthcare) equilibrated in 20 mM
Tris–HCl, 150 mMNaCl, pH 8.0 buffer, at 0.4 ml/min. The molecular
size and weight of the protein were also estimated by dynamic
light scattering (DLS; Nonozetasizer, Malvern). The DLS measure-
ments were performed at room temperature, using a protein sam-
ple at 0.5 mg/ml in the same buffer (20 mM Tris, 150 mM NaCl, pH
8.0).Adsorption assay
To evaluate the human laforin-CBM substrate afﬁnity and spec-
iﬁcity, adsorption assays using starch were carried out. The puri-
ﬁed protein samples (0.25 mg/ml) were centrifuged (13 000 rpm,
10 min, 4 C) to remove any precipitated protein, and then the pro-
tein was mixed with 50 mg of starch (previously washed with
50 mM Tris–HCl, 150 mM NaCl, pH 7.4 buffer) for 1 h at 4 C. The
mixture was centrifuged (13 000 rpm, 10 min, 4 C) and the super-
natant analyzed by SDS–PAGE. The starch was washed with buffer
(3X 0.3 ml) and the recombinant CBM was eluted from starch with
a 5 mg/ml glycogen solution (0.3 ml, at 4 C for 1 h). The starch was
then treated with buffer containing 2% SDS (0.3 ml, at 95 C for
5 min) in order to analyze the protein that remained adsorbed after
glycogen elution.Results
Recombinant laforin’s CBM expression and puriﬁcation
Several strategies were used, attempting the production of the
soluble CBM, including periplasmic secretion (pET25b) and fusion
with GST – a solubility enhancer tag. Fig. 1 summarizes these ap-
proaches and the main results obtained under the conditions
tested. Using pET25b, the recombinant protein was not detected
in the periplasmic fraction under the conditions tested. The protein
was rather expressed in the cytoplasmatic fraction and only in the
presence of arginine and CHAPS the puriﬁcation was possible,
using the IMAC system. Nevertheless, native PAGE and DLS analy-
ses indicated protein aggregation and the adsorption assay showed
that CBM was not functional (data not shown).
When fused to GST, although soluble, the puriﬁed protein was
obtained in very low quantities and the CBM did not present starch
afﬁnity (data not shown).
Finally, the solubilization and refolding of IBs was the approach
leading to the functional CBM; only those results will be presented
in this work.
Escherichia coli BL21 star cells transformed with pET29a-CBM
vector were grown in 1 L of LB medium at 37 C and induced with
0.5 mM IPTG for 3 h. Table 2 summarizes the results obtained
using the IBs refolding protocol.
Fig. 2 shows the SDS–PAGE analysis of the protein obtained in
the insoluble fraction and, after the washing step, recombinant
protein showed 68% purity (Fig. 2C, lane 1). The protein has an
apparent molecular weight close to the expected (22 kDa) and
even under denaturing condition is possible to detect the dimeric
form (44 kDa). This result is in agreement with the previously
described resistance of laforin to dimer separation, prior to
SDS–PAGE [26]. During the refolding step, about 40% (62.6 mg) of
protein had precipitated, but the insoluble material was success-
fully removed by ultracentrifugation prior to its application onto
HiLoad 26/60 Superdex 200 column. The protein detected on the
major peak (Fig. 2A), corresponding to the tetramer form of the
protein, was loaded onto Mono Q column in order to separate
the different protein conformation (Fig. 2B). The puriﬁed protein
was then analyzed and the results from Superdex 200 10/300 GL
column suggested that protein is a dimer. The difference in the
oligomerization state between the preparative and analytical
Superdex 200 columns resides on the fact that the protein is con-
verted into a dimer in the presence of 150 mM of NaCl, which is
not present during preparative puriﬁcation (data not shown).
Native PAGE analysis and gel ﬁltration chromatography (Super-
dex 200 10/300 GL equilibrated with 20 mM Tris–HCl, 150 mM
NaCl, pH 8.0 buffer) of the highest peak, collected fromMono Q col-
umn (Fig. 2B and C, lane 3) showed that the refolded protein was
not aggregated and exhibits the size corresponding to the dimeric
form (44 kDa) and is highly puriﬁed (Fig. 3A and B). In addition, the
DLS analyses of the sample (in buffer containing 150 mM of NaCl)
detected a particle with hydrodynamic diameter of 6.5 nm, corre-
sponding to a 44 kDa protein (Fig. 3C) using an empirical calibra-
tion developed by Malvern Instruments, thus conﬁrming the
dimerization of the isolated protein. The polydispersity of the sam-
ple was 0.15% and the result shown corresponds to an average of
10 measurements.The ability of the recombinant laforin’s CBM to bind carbohydrates
The functionality of the recombinant protein, i.e., its ability to
bind starch, was evaluated using an adsorption assay. Brieﬂy, the
proteinwas incubatedwith starch and after 1 h, threewashing steps
were performedwith buffer (50 mMTris–HCl, 150 mMNaCl, pH 7.4
Fig. 1. Summary of strategies and results obtained under the conditions tested.
Table 2
Puriﬁcation table.
Total protein
(mg)
Estimated amount
of total CBM
Yield (%) Purity (%)
Cell extract 306 85.7 100 28
Refolded protein 106 72.1 84 68
Applied to Sx200 43.4 34.7 40 80
Sx200 #15–18 33 29.7 35 90
Mono Q #9–14 12.8 11.5 13 90
The starting material was 1 L of E. coli expressing CBM-RGD (weight of wet bacteria:
3.74 g). Purity was determined by analysis of SDS–PAGE band intensities using the
Quantity One software, version 4.6 (BioRad).
172 S. Moreira et al. / Protein Expression and Puriﬁcation 74 (2010) 169–174buffer). Since no protein has been removed (Fig. 4 – lanes W1 and
W2), the elution was performed by incubating the starch moiety
with a glycogen (5 mg/ml) containing buffer. After 1 h, the sample
was centrifuged and both the supernatants (E1 and E2) and the pel-
lets (P1 and P2) were analyzed by SDS–PAGE. The results showed
that the glycogen was effective in promoting the desorption of
CBM, although not completely, sincemost of the CBMwas still pres-
ent in the pellet fraction (Fig. 4 – lanes P1 and P2).Fig. 2. CBM-RGD chromatographic puriﬁcation. (A) The refolding, after concentrated, so
20 mM Tris, 0.4 M urea, pH 8.0; (B) the fraction from the second protein peak from Superd
urea, pH 8.0. Elution was done by a gradient of NaCl; (C) SDS–PAGE analysis: (1) Samp
Superdex 200; (3) Highest peak (eluted at about 20 ml) from Mono Q; (4) Molecular weDiscussion
This is the ﬁrst report on the expression of the unusual laforin-
CBM. The production of functional CBM, now achieved, will allow
the structural characterization, by crystallography, contributing
for the elucidation of mechanistic aspects related to the Lafora dis-
ease. Several biomedical applications can be envisioned using this
human CBM, such as tag molecule for adsorbing small bioactive
peptides to starch-based biomedical materials. The expression of
soluble and functional heterologous proteins may be a difﬁcult
task, especially for eukaryotic proteins [27]. The heterologous bac-
terial expression systems remain the most attractive ones due to
low cost, high productivity, the well-known genetics and the large
number of compatible molecular tools available [28,29]. Usually,
overexpressed recombinant proteins accumulate either in the
cytoplasm and/or in the periplasmic space. However, overexpres-
sion of recombinant proteins in bacterial hosts frequently results
in IBs, which are amorphous granules of misfolded protein with
no biological activity [28,30–32]. The IBs formation frequently
occurs, when overexpressing eukaryotic proteins, since post-
translation modiﬁcation processes are often required for their cor-
rect folding and functionality [27,33,34]. Commonly, the proteinlution was applied to a HiLoad 26/60 Superdex 200 column pre-equilibrated with
ex 200 were loaded onto a 1 ml Mono Q column equilibrated with 20 mM Tris, 0.4 M
le applied to Superdex 200; (2) Second peak (eluted at about 150 – 200 ml) from
ight Standard.
Fig. 3. Analysis of the protein by (A) gel ﬁltration chromatography using a Superdex
200 10/300 GL equilibrated with 20 mM Tris, 150 mM NaCl, pH 8.0 buffer that had
been previously calibrated using the GE Healthcare gel ﬁltration molecular weight
calibration kit (highlighted box), the triangles indicate the elution volumes of MW
markers used for column calibration, (B) native PAGE and (C) DLS analysis of
puriﬁed protein in buffer containing 150 mM of NaCl. BSA was used as control.
Fig. 4. SDS–PAGE of CBM-RGD adsorption assay to starch. Initial protein (I),
washing fraction (W), elution fraction of CBM-RGD with buffer containing glycogen
(E) and pellet (P). All steps were done in duplicate and using different protein stock
preparations.
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poor recovery yields and the customization of the refolding condi-
tions for each target protein. Furthermore, the re-solubilization
procedures may affect the integrity of the refolded proteins
[27,28]. However, in this study, the functional CBM could be ob-
tained only through IBs solubilization and refolding.
Several strategies to enhance the solubility of recombinant pro-
teins are available, among them the use of fusion tags and optimi-
zation of the growth and induction conditions [35–37]. In this
work, several expression systems were used, attempting to pro-
duce soluble CBM, including the fusion with GST-tag, secretion to
periplasmic space (where protein was expected to be mostly solu-
ble and correctly processed), different expression hosts, different
growth and induction conditions; nevertheless, the recombinant
CBM was always obtained in the insoluble fraction or, when
soluble, aggregate, lacking starch afﬁnity (data not shown). More-
over, results using chaperone co-expression and Pichia pastoris
expression systems (unpublished results) also lead to aggregated
recombinant CBM. The full protein laforin, comprising the two
modules, has been expressed by other authors as a fusion protein(with GST, 6x-His) in E. coli. This protein showed phosphatase
activity on model substrate and afﬁnity for glycogen and starch
[1–3,6,38,39]; however, laforin was described as aggregating eas-
ily, and indeed it presents different solubility depending on the
fused tag [6], with 6xHIS-tagged laforin being less soluble than
GST-laforin.
Taken together, the results obtained with the different expres-
sion systems point towards the CBM domain being less soluble
than the full-length laforin. Indeed, the same expression system
effective for the production of the soluble full-length laforin is
not suitable for CBM alone.
It is known that, in vivo, the dimerization of laforin, through a
CBM–CBM interaction, is essential for its phosphatase activity
[26,40]. The protein obtained by inclusion bodies solubilization
and refolding presented different oligomerization state depending
on the presence of salt in the buffer. The DLS analyses of recombi-
nant protein, in buffer containing 150 mM of NaCl, indicated that
protein presented a hydrodynamic diameter of 6.5 nm, corre-
sponding to a protein with 44 kDa. The DLS analyses conﬁrm the
gel ﬁltration chromatography results, suggesting that the protein
obtained is the pure CBM dimmer, in buffer containing 150 mM
of NaCl. Furthermore, the CBM adsorbed to starch was partially
eluted using glycogen, indicating its functionality; however, a con-
siderable amount of CBM remained in the starch-pellet, probably
due to the stronger binding of laforin towards starch than glyco-
gen, as previously reported [8] or to the presence of inactive mate-
rial that precipitated on starch particles.
Further work including assays using CBM-RGD on dextrin
hydrogel, as described in a previous work for bacterial CBM [22],
and the evaluation in cell adhesion and proliferation on biomate-
rial; the production of novel recombinant proteins containing the
CBM fused to other bioactive peptides; and the study of the
three-dimensional structure of the CBM can be considered.
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